TB-500 vs KPV (2026): Evidence & Legal Status Compared

TB-500 and KPV are both unapproved research peptides studied for wound healing and inflammation, with no published human RCT. Both are preclinical, though TB-500 has one recruiting early-phase trial and KPV has none registered. Both face the FDA's July 23, 2026 compounding vote. Research information only, not medical advice.

Last updated:

Independent information index. We do not sell vendor placements or take affiliate commissions on peptide sales. Read our affiliate disclosure .

TB-500 KPV
Evidence level (highest) Preclinical (cell and animal studies) Preclinical (cell and animal studies)
Published human RCT None as of June 2026 None as of June 2026
Active registered trial Early-phase (cardiac, thymosin β4 fragment), recruiting None registered
Most-studied use Wound healing, soft-tissue and cardiac repair Gut inflammation (IBD/colitis models) and wound healing
Molecular identity Thymosin β4 / actin-binding fragment α-MSH C-terminal tripeptide (Lys-Pro-Val)
US approval status Unapproved drug Unapproved drug
FDA 503A compounding Under review, PCAC vote Jul 23, 2026 Under review, PCAC vote Jul 23, 2026
Evaluated indication (FDA) Wound healing Wound healing and inflammatory conditions
Anti-doping Non-approved substance — athletes should treat as prohibited Non-approved substance — athletes should treat as prohibited
EU marketing authorization None None

Verdict

Neither peptide is a proven human therapeutic in 2026, and neither is approved or legally sold for human use. The indexed evidence for both is preclinical, and the only concrete difference in the research pipeline is that TB-500 has one recruiting early-phase trial while KPV has none. They are studied for overlapping reasons — wound healing and inflammation — but through different molecules: TB-500 derives from thymosin β4, KPV is a fragment of α-MSH. Both share the same July 2026 FDA compounding vote. A buying guide that ranks one as clearly proven is selling a distinction the data does not support.

People research TB-500 and KPV together because both show up in online “healing and anti-inflammatory” protocols, often in the same stack. The honest comparison is narrower than the marketing: on the evidence and the legal status, the two land in nearly the same place, separated by one thin difference in the research pipeline. The table above is the row-by-row breakdown. Below is what each row means.

TB-500 vs KPV: the short version

Both are research peptides with preclinical evidence, no published human randomized controlled trial, no approval in any major jurisdiction, and a shared date with the same FDA compounding committee on July 23, 2026. The one concrete difference is that TB-500 has a recruiting early-phase human trial and KPV has none. If you are choosing between them expecting one to be clearly proven, the data does not support that framing.

Evidence: both preclinical

What is known about either molecule comes from cell and animal studies. TB-500, a fragment related to thymosin β4, has been studied for soft-tissue and cardiac repair; as of 2026 there is one recruiting early-phase trial of a thymosin β4 fragment. KPV, the C-terminal tripeptide of α-MSH, has been studied for its anti-inflammatory action, mostly in inflammatory-bowel-disease and colitis models, with no registered human trial. Neither has a randomized controlled trial, the bar for “this works in people.” For how we weigh these tiers, see our how we grade evidence explainer, the full TB-500 evidence and regulatory record, and the KPV evidence and regulatory record.

What each is studied for

The two are stacked for “healing,” but the mechanisms under study differ. TB-500 work centers on actin-binding and cell migration in wound and cardiac models. KPV work centers on the melanocortin pathway and inflammation, with the gut as the main model system. So the overlap is the goal, not the biology — one is tissue-repair focused, the other inflammation focused.

Regulation: the same July 2026 vote

Both were removed from the FDA 503A “do not compound” list in April 2026, which did not make them compoundable. The Pharmacy Compounding Advisory Committee votes on both on July 23, 2026 — for TB-500 the evaluated indication is wound healing, for KPV it is wound healing and inflammatory conditions. We track the meeting in the July 2026 FDA peptide meeting, explained. Neither carries a marketing authorization in the European Union, and as non-approved substances both should be treated as prohibited under anti-doping rules.

So which one, if either?

The defensible answer in 2026 is that neither is an established human therapeutic, and the choice is between two unproven options for an overlapping goal. The only sourced edge is that TB-500 has a registered trial in progress and KPV does not. Everything else — approval status, compounding status, EU authorization — converges. Watch the July 2026 vote for the next real change.

Research information only. Neither TB-500 nor KPV is approved for human use. Talk to a licensed physician before considering any peptide.

FAQ

Is TB-500 or KPV FDA approved?
Neither. Both are unapproved drugs in the United States. They were removed from the FDA "do not compound" list in April 2026 but are not eligible for compounding. The Pharmacy Compounding Advisory Committee votes on both on July 23, 2026.
Which one has better human evidence?
Both rest on preclinical data — cell and animal studies. Neither has a published randomized controlled trial. The only pipeline difference is that TB-500 has one recruiting early-phase trial; KPV has no registered trial.
Are they legal to use?
Both are sold as research only and are not authorized for human use in the US or EU. As non-approved substances, athletes should treat both as prohibited under anti-doping rules. This page is research information, not medical or legal advice.

Sources